Justin Lee Grodin, MD, MPH, FACC
Associate Professor of Medicine

Printed as of 11/20/2026

Disclosures

Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Alexion	Consultant Fees/Honoraria	Modest (< $5,000)	Heart Failure and Cardiomyopathies
Alnylam	Speaker's Bureau	Modest (< $5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< $5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< $5,000)	Heart Failure and Cardiomyopathies
Eidos/BridgeBio	Consultant Fees/Honoraria	Modest (< $5,000)	Heart Failure and Cardiomyopathies
Intellia	Consultant Fees/Honoraria	Modest (< $5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= $5,000)	Heart Failure and Cardiomyopathies
Pfizer	Consultant Fees/Honoraria	Modest (< $5,000)	Heart Failure and Cardiomyopathies
Pfizer Inc	Research/Research Grants ‡ NCT05489523	Significant (>= $5,000)	Heart Failure and Cardiomyopathies
Tenax Therapeutics	Data Safety Monitoring Board	Modest (< $5,000)	Heart Failure and Cardiomyopathies
Ultromics	Consultant Fees/Honoraria	Modest (< $5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (8)

Trial Name	Trial Sponsor	Trial Funding Source
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM (DepleTTR-CM)	Alexion	
CARDIOTTRansform	AstraZeneca Pharmaceuticals	
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants	Eidos/BridgeBio	
ACT-EARLY	Eidos/BridgeBio	
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)	Intellia	
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)	Ionis / Astra-Zeneca	
MUSIC-HFrEF1	Sardocor	
MUSIC-HFpEF	Sardocor Corp.	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/14/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/14/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/14/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/14/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.